Skip to content
Back to Investors
24Haymarket

24Haymarket

Venture Capital

24Haymarket is a private capital firm focused on early stage venture and growth equity investments in the UK.


Recent investments

Series A
£13.0M

The privacy engineering software company raised £13m from Partech Ventures, CME Ventures and Salesforce Ventures to scale its operations.

"Advanced analytics and machine learning applications are fuelled by data, which is often sensitive. Privitar’s software enables our customers to innovate rapidly while maintaining an uncompromising approach to data privacy. We believe the use of technological controls to protect privacy is essential to preserve customer trust in the data-driven economy."
— Jason du Preez, CEO
£1.5M

The clean tech business has closed the investment to fund its continued growth in the UK and overseas markets.

"24Haymarket is delighted to be supporting Kelda with a £1.5m equity investment to help scale the business now that it has proven its technology. We believe that the compelling environmental and economic benefits of Kelda’s innovative, patented shower systems make this a global product wherever water and energy resources are valued. We are also delighted that we have already been able to leverage 24Haymarket’s network to provide sales leads, potential resources and learnings from other portfolio companies to assist the management team in executing and realising its business plan."
— Charlie Green, Investor
$7.0M

The investment round was led by an Asian corporate investor alongside existing backers to fund the commercial launch of Cyto-Mine.

"Sphere Fluidics Limited has recently successfully developed an alpha-version of its single cell analysis and characterization system (Cyto-Mine® for the biopharmaceutical discovery and development market. We have also convinced several leading biopharmaceutical companies to fund development of this system – indicating the global potential of the product. This new funding will used to develop the manufactured version of Cyto-Mine® (see image below) and enable its commercial launch later this year. This system is transformational for the Biopharmaceutical market."
— Frank Craig, CEO